IHS Chemical Week

Regions :: North America :: U.S.

Lonza and BioWa sign license agreements with Pfizer

12:28 AM MDT | July 30, 2013 | Deepti Ramesh

Lonza and BioWa (La Jolla, CA), a wholly owned subsidiary of biopharmaceutical company Kyowa Hakko Kirin (Tokyo), have entered into research agreements with Pfizer allowing the use of the Potelligent CHOK1SV cell line in the R&D of multiple proprietary antibodies in Pfizer’s pipeline, Lonza says. Potelligent CHOK1SV is a host cell line for manufacturing recombinant antibodies. The cell line combines BioWa’s engineered glycosylation Potelligent technology with Lonza’s GS Gene Expression System. The GS system includes Lonza’s...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week subscriber yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine a year in print or digital format
  • Real time news and analysis on chemweek.com 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now


contact us | about us | privacy policy | sitemap

ihsCopyright © IHS, Inc.All rights reserved.Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa